Fig. 2: Median progression-free survival (mPFS) and median overall survival (mOS) results with their 95% confidence interval (CI 95%) for the STIC CTC trial, in the four subgroups defined by the clinician’s choice of therapy (Clinhigh or Clinlow) and the CTC count (CTChigh or CTClow).
From: Circulating tumor cells in breast cancer: clinical validity and utility
HR: hazard ratio.
